Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while ...

More than half of severe COVID-19 survivors show fibrotic-like lung abnormalities even 3 years after infection, especially ...

Findings reveal that a structured home rehabilitation program boosts lung function and quality of life in bronchiectasis ...

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Paediatric-onset bronchiectasis leads to more severe disease than adult-onset, highlighting need for early, tailored care.

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

The two companies will scale production for a novel recombinant version of alpha-1 antitrypsin targeting lung diseases.

Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead ...

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially ...

Bronchiectasis is one of the most neglected chronic lung diseases despite the fact it impacts 300,000 people in the UK ...

Bronchiectasis, a lesser-known lung condition that often has no clear cause and is incurable, can lead to an overproduction of phlegm, causing a variety of other problems and presenting some ...